Haleon Shares Fall as Weak Sales Growth Overshadows Profit Beat

Haleon PLC shares declined on Thursday as investor concerns over sluggish sales growth and a challenging outlook overshadowed a first-half profit that exceeded analyst expectations. The consumer health giant now faces a steep climb in the second half of the year to meet its medium-term revenue targets.

Results Under Scrutiny

The maker of Sensodyne toothpaste and Theraflu cold medicine reported a first-half adjusted operating profit of £1.36 billion ($1.81 billion), topping a company-compiled consensus forecast of £1.32 billion. However, the market focused on a weaker top-line performance, with organic revenue growing by just 2.6%, according to a report from Reuters.

This growth figure, while in line with forecasts, falls significantly short of the company's medium-term annual target of 4% to 6%. The discrepancy raised doubts about Haleon's ability to hit its full-year goals, causing its shares to fall by as much as 3.3% during trading. Analysts at Jefferies noted the results were "not quite good enough," arguing that stronger underlying sales growth was needed.

Regional and Category Headwinds

A breakdown of the results reveals significant regional and categorical weaknesses that weighed on overall growth. A weak flu season and cautious consumer spending were key factors.

Ad

• European Demand: Sales in Europe were nearly flat as consumers tightened their belts.
• Respiratory Sales: Revenue from respiratory products like Theraflu and Flonase fell sharply by 6.5%, a steeper decline than the 3.4% drop in the first quarter.
• North American Strength: The company's largest market, North America, was a relative bright spot, posting organic revenue growth of 3.1% in the second quarter, which was ahead of expectations.

Management Eyes Second-Half Rebound

Despite the headwinds, Haleon's leadership expressed confidence in a stronger performance for the remainder of the year. CEO Brian McNamara told analysts he expects a "stronger second half than first half," driven by a recovery in demand for cough-and-cold products and growth in some emerging markets.

The company is also navigating rising freight costs linked to conflict in the Middle East. While costs are expected to rise as hedging arrangements expire, McNamara told Reuters that Haleon can absorb the increase through gross margin improvements "without needing to do anything around pricing to cover for it."